Bill Wexler's Dog Pound Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound

REFR 1.560

-2.5%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Hank who wrote (2137)	7/14/1999 10:59:00 AM
From: Mike M	Read Replies (1) of 10293

I might point out that the only way pleconaril will ever be able to effectively compete with OTC medicines like zicam is if IT becomes approved for OTC sales. My point to someone else who asked if it weren't a competitor to Zicam... it will be a prescription drug that will be used for patients who suffer severe viral symptoms such as meningitis. The study on viral meningitis were disappointing and are not likely to even be approved...or may not even be continued.... Even if VPHM tried to get Dr's to prescribe it for people with an average cold, how many people would bother (especially if they didn't have prescription coverage)? Especially if it only offers "3 days" of relief...according to the study... If you folks are looking for a stock that is overpriced you may want to take a closer look at this one. If the NEJM article on ZICAM is released soon, can you imagine what that would do to this stock?...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next